Latest Darmstadt Stories

MS LifeLines® Call Center Earns J.D. Power and Associates Re-Certification for Customer Service Excellence in Providing Support Services to the MS Community

2013-05-28 08:29:43

Certification marks second consecutive year J.D. Power and Associates recognizes MS LifeLines for providing an outstanding customer service experience ROCKLAND, Mass. and NEW YORK, May 28, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the MS LifeLines(® )call center earned re-certification for customer service excellence in providing support services to the multiple sclerosis (MS) community through the...

EMD Serono and Pfizer Announce FDA Approval of Rebif® Rebidose® (interferon beta-1a)

2013-01-03 12:24:27

ROCKLAND, Mass. and NEW YORK, Jan. 3, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Rebif(®) Rebidose(®) (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). (Logo: http://photos.prnewswire.com/prnh/20130103/SF36310LOGO) (Logo:...

EMD Serono, Inc. and Fast Forward, LLC Announce Recipients of Funding for Multiple Sclerosis Research

2012-12-20 08:27:04

ROCKLAND, Mass. and NEW YORK, Dec. 20, 2012 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Fast Forward LLC, a wholly-owned subsidiary of the National Multiple Sclerosis Society, today announced the third group of recipients to receive funding through their collaboration, which is designed to accelerate innovation and commercial development of multiple sclerosis (MS) therapies. (Logo: http://photos.prnewswire.com/prnh/20121220/SF32295LOGO-a)...

EMD Serono Launches One Million Euro Research Grant for Multiple Sclerosis Innovation

2012-10-11 07:28:54

ROCKLAND, Mass., Oct. 11, 2012 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress in Lyon, France, that the company has initiated a new global research award to improve understanding of multiple sclerosis for the ultimate benefit of patients. (Logo: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-a) (Logo:...

Control Of The Metop-B Weather Satellite Handed Over To EUMETSAT By ESA

2012-09-21 10:31:28

Yesterday, at 18:30 local time EUMETSAT took control of Metop-B operations, following the three-day Launch and Early Orbit Phase (LEOP) conducted by the European Space Operations Centre (ESOC) of the European Space Agency (ESA). The handover follows the launch of Metop-B on 17 September. Since Monday evening, teams at ESA’s European Space Operations Centre in Darmstadt, Germany, have been busy day and night during the Launch and Early Orbit Phase. As planned, they checked all of...

EMD Serono Expands the Grant for Fertility Innovation (GFI) Program to Include U.S. Investigators

2012-09-18 06:28:34

ROCKLAND, Mass., Sept. 18, 2012 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the company has expanded its global program named Grant for Fertility Innovation (GFI) so that it is available to U.S. investigators. (Logo: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-a) (Logo: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-b) Announced for the first time in 2009, GFI is dedicated to transforming...

Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA

2012-09-05 22:22:16

COPENHAGEN, Denmark, September 6, 2012 /PRNewswire/ -- - Symphogen Will Host a Conference Call Today (Thursday 6 September 2012) to Discuss the Announcement at 11:30 CET/ 10:30 BST, Details on How Access This Call and the Accompanying Presentation are Below. - A novel investigational antibody mixture targeting the epidermal growth factor receptor (EGFR) Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of...

Designing The Interplanetary Web

2012-04-16 05:00:43

Reliable Internet access on the Moon, near Mars or for astronauts on a space station? How about controlling a planetary rover from a spacecraft in deep space? These are just some of the pioneering technologies that ESA is working on for future exploration missions. What do observation or navigation satellites orbiting Earth have in common with astronauts sending images in real time from the International Space Station? They all need to send data back home. And the complexity of sharing...

MS LifeLines® Earns J.D. Power and Associates Call Center Certification for Customer Service Excellence in Providing Support Services to the MS Community

2012-01-23 07:00:00

ROCKLAND, Mass. and NEW YORK, Jan. 23, 2012 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the MS LifeLines® call center earned certification through the prestigious J.D. Power and Associates Call Center Program(SM)( )after a thorough audit of customer satisfaction practices over several months in 2011. This is the first time J.D. Power and Associates has recognized a pharmaceutical call center for...

GSI Group, Inc. Schedules Third Quarter Earnings Release and Conference Call for November 10, 2011

2011-10-20 13:49:00

BEDFORD, Mass., Oct. 20, 2011 /PRNewswire/ -- GSI Group, Inc., (NASDAQ: GSIG) will release its third quarter 2011 results, after the market close, on Thursday, November 10, 2011. The Company will host a conference call on November 10, 2011 at 5:00 p.m. ET to discuss these results. John A. Roush, chief executive officer, and Robert Buckley, chief financial officer, will host the conference call. (Logo: http://photos.prnewswire.com/prnh/20110719/MM38089LOGO) To access the...